BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

445 related articles for article (PubMed ID: 24423344)

  • 1. Hyperandrogenemia predicts metabolic phenotype in polycystic ovary syndrome: the utility of serum androstenedione.
    O'Reilly MW; Taylor AE; Crabtree NJ; Hughes BA; Capper F; Crowley RK; Stewart PM; Tomlinson JW; Arlt W
    J Clin Endocrinol Metab; 2014 Mar; 99(3):1027-36. PubMed ID: 24423344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 11-Oxygenated C19 Steroids Are the Predominant Androgens in Polycystic Ovary Syndrome.
    O'Reilly MW; Kempegowda P; Jenkinson C; Taylor AE; Quanson JL; Storbeck KH; Arlt W
    J Clin Endocrinol Metab; 2017 Mar; 102(3):840-848. PubMed ID: 27901631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Steroid metabolome profiling of follicular fluid in normo- and hyperandrogenic women with polycystic ovary syndrome.
    Yang Z; Zhou W; Zhou C; Zhou Y; Liu X; Ding G; Hu Y; Pan J; Sheng J; Jin L; Huang H
    J Steroid Biochem Mol Biol; 2021 Feb; 206():105806. PubMed ID: 33340681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Measurement of selected androgens using liquid chromatography-tandem mass spectrometry in reproductive-age women with Type 1 diabetes.
    Gunness A; Pazderska A; Ahmed M; McGowan A; Phelan N; Boran G; Taylor AE; O'Reilly MW; Arlt W; Moore K; Behan LA; Sherlock M; Gibney J
    Hum Reprod; 2018 Sep; 33(9):1727-1734. PubMed ID: 30020477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME--PART 1.
    Goodman NF; Cobin RH; Futterweit W; Glueck JS; Legro RS; Carmina E; ; ;
    Endocr Pract; 2015 Nov; 21(11):1291-300. PubMed ID: 26509855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyperandrogenemia in polycystic ovary syndrome: exploration of the role of free testosterone and androstenedione in metabolic phenotype.
    Lerchbaum E; Schwetz V; Rabe T; Giuliani A; Obermayer-Pietsch B
    PLoS One; 2014; 9(10):e108263. PubMed ID: 25310562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reconciling the definitions of polycystic ovary syndrome: the ovarian follicle number and serum anti-Müllerian hormone concentrations aggregate with the markers of hyperandrogenism.
    Dewailly D; Pigny P; Soudan B; Catteau-Jonard S; Decanter C; Poncelet E; Duhamel A
    J Clin Endocrinol Metab; 2010 Sep; 95(9):4399-405. PubMed ID: 20610596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the efficacy of different androgens measured by LC-MS/MS in representing hyperandrogenemia and an evaluation of adrenal-origin androgens with a dexamethasone suppression test in patients with PCOS.
    Chen F; Chen M; Zhang W; Yin H; Chen G; Huang Q; Yang X; Chen L; Lin C; Yin G
    J Ovarian Res; 2021 Feb; 14(1):32. PubMed ID: 33583431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Defining Hyperandrogenism in Women With Polycystic Ovary Syndrome: A Challenging Perspective.
    Pasquali R; Zanotti L; Fanelli F; Mezzullo M; Fazzini A; Morselli Labate AM; Repaci A; Ribichini D; Gambineri A
    J Clin Endocrinol Metab; 2016 May; 101(5):2013-22. PubMed ID: 26964728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-invasive urinary metabolomics reveals metabolic profiling of polycystic ovary syndrome and its subtypes.
    Zhou W; Hong Y; Yin A; Liu S; Chen M; Lv X; Nie X; Tan N; Zhang Z
    J Pharm Biomed Anal; 2020 Jun; 185():113262. PubMed ID: 32222648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The association of body mass index and biochemical hyperandrogenaemia in women with and without polycystic ovary syndrome.
    Yasmin E; Balen AH; Barth JH
    Eur J Obstet Gynecol Reprod Biol; 2013 Feb; 166(2):173-7. PubMed ID: 23102586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Prevalence of Polycystic Ovary Syndrome, Its Phenotypes and Cardio-Metabolic Features in a Community Sample of Iranian Population: Tehran Lipid and Glucose Study.
    Farhadi-Azar M; Behboudi-Gandevani S; Rahmati M; Mahboobifard F; Khalili Pouya E; Ramezani Tehrani F; Azizi F
    Front Endocrinol (Lausanne); 2022; 13():825528. PubMed ID: 35299965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lower insulin sensitivity differentiates hirsute from non-hirsute Sicilian women with polycystic ovary syndrome.
    Amato MC; Galluzzo A; Merlino S; Mattina A; Richiusa P; Criscimanna A; Giordano C
    Eur J Endocrinol; 2006 Dec; 155(6):859-65. PubMed ID: 17132756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Exploration of the classification of polycystic ovarian syndrome].
    Lin JF; Li X; Zhu MW
    Zhonghua Fu Chan Ke Za Zhi; 2006 Oct; 41(10):684-8. PubMed ID: 17199924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of clinical and laboratory characteristics of cases with polycystic ovarian syndrome based on Rotterdam's criteria and women whose only clinical signs are oligo/anovulation or hirsutism.
    Hassa H; Tanir HM; Yildiz Z
    Arch Gynecol Obstet; 2006 Jul; 274(4):227-32. PubMed ID: 16691383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adrenal androgen excess and body mass index in polycystic ovary syndrome.
    Moran C; Arriaga M; Arechavaleta-Velasco F; Moran S
    J Clin Endocrinol Metab; 2015 Mar; 100(3):942-50. PubMed ID: 25514100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 17-hydroxyprogesterone responses to gonadotropin-releasing hormone disclose distinct phenotypes of functional ovarian hyperandrogenism and polycystic ovary syndrome.
    Pasquali R; Patton L; Pocognoli P; Cognigni GE; Gambineri A
    J Clin Endocrinol Metab; 2007 Nov; 92(11):4208-17. PubMed ID: 17785360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characteristics and contributions of hyperandrogenism to insulin resistance and other metabolic profiles in polycystic ovary syndrome.
    Huang R; Zheng J; Li S; Tao T; Ma J; Liu W
    Acta Obstet Gynecol Scand; 2015 May; 94(5):494-500. PubMed ID: 25711494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High salivary testosterone-to-androstenedione ratio and adverse metabolic phenotypes in women with polycystic ovary syndrome.
    Münzker J; Lindheim L; Adaway J; Trummer C; Lerchbaum E; Pieber TR; Keevil B; Obermayer-Pietsch B
    Clin Endocrinol (Oxf); 2017 Apr; 86(4):567-575. PubMed ID: 28039871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Salivary testosterone measurement in women with and without polycystic ovary syndrome.
    Sathyapalan T; Al-Qaissi A; Kilpatrick ES; Dargham SR; Adaway J; Keevil B; Atkin SL
    Sci Rep; 2017 Jun; 7(1):3589. PubMed ID: 28620242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.